image
Healthcare - Medical - Instruments & Supplies - NYSE - CA
$ 10.9
-4.13 %
$ 3.85 B
Market Cap
-10.69
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BLCO stock under the worst case scenario is HIDDEN Compared to the current market price of 10.9 USD, Bausch + Lomb Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BLCO stock under the base case scenario is HIDDEN Compared to the current market price of 10.9 USD, Bausch + Lomb Corporation is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one BLCO stock under the best case scenario is HIDDEN Compared to the current market price of 10.9 USD, Bausch + Lomb Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart BLCO

image
$21.0$21.0$20.0$20.0$19.0$19.0$18.0$18.0$17.0$17.0$16.0$16.0$15.0$15.0$14.0$14.0$13.0$13.0$12.0$12.0$11.0$11.0$10.0$10.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
4.77 B REVENUE
15.15%
162 M OPERATING INCOME
24.62%
-305 M NET INCOME
-22.98%
232 M OPERATING CASH FLOW
1464.71%
-412 M INVESTING CASH FLOW
80.46%
178 M FINANCING CASH FLOW
-91.43%
1.13 B REVENUE
-11.48%
-83 M OPERATING INCOME
-95.40%
-211 M NET INCOME
-10450.00%
-25 M OPERATING CASH FLOW
-113.64%
-116 M INVESTING CASH FLOW
37.30%
31 M FINANCING CASH FLOW
-78.77%
Balance Sheet Bausch + Lomb Corporation
image
Current Assets 2.79 B
Cash & Short-Term Investments 305 M
Receivables 1.03 B
Other Current Assets 1.46 B
Non-Current Assets 10.7 B
Long-Term Investments 0
PP&E 1.48 B
Other Non-Current Assets 9.2 B
7.62 %10.82 %11.03 %68.28 %Total Assets$13.5b
Current Liabilities 1.74 B
Accounts Payable 389 M
Short-Term Debt 40 M
Other Current Liabilities 1.31 B
Non-Current Liabilities 5.19 B
Long-Term Debt 4.74 B
Other Non-Current Liabilities 443 M
5.62 %18.90 %68.51 %6.40 %Total Liabilities$6.9b
EFFICIENCY
Earnings Waterfall Bausch + Lomb Corporation
image
Revenue 4.77 B
Cost Of Revenue 1.87 B
Gross Profit 2.9 B
Operating Expenses 2.76 B
Operating Income 162 M
Other Expenses 467 M
Net Income -305 M
5b5b4b4b3b3b2b2b1b1b00(1b)(1b)5b(2b)3b(3b)162m(467m)(305m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
60.79% GROSS MARGIN
60.79%
3.39% OPERATING MARGIN
3.39%
-6.64% NET MARGIN
-6.64%
-4.90% ROE
-4.90%
-2.35% ROA
-2.35%
1.79% ROIC
1.79%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bausch + Lomb Corporation
image
700m700m600m600m500m500m400m400m300m300m200m200m100m100m00(100m)(100m)(200m)(200m)20192019202020202021202120222022202320232024202420252025
Net Income -305 M
Depreciation & Amortization 436 M
Capital Expenditures -291 M
Stock-Based Compensation 92 M
Change in Working Capital 0
Others 19 M
Free Cash Flow -59 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bausch + Lomb Corporation
image
Wall Street analysts predict an average 1-year price target for BLCO of $21.7 , with forecasts ranging from a low of $18 to a high of $25 .
BLCO Lowest Price Target Wall Street Target
18 USD 65.14%
BLCO Average Price Target Wall Street Target
21.7 USD 98.78%
BLCO Highest Price Target Wall Street Target
25 USD 129.36%
Price
Max Price Target
Min Price Target
Average Price Target
262624242222202018181616141412121010Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 13
6. Ownership
Insider Ownership Bausch + Lomb Corporation
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
19.9 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
505 K USD 1
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO NEW YORK CITY, NY / ACCESS Newswire / May 7, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. prnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO NEW YORK, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch + Lomb Corporation - BLCO NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE:BLCO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. accessnewswire.com - 2 weeks ago
Bausch + Lomb Corporation (BLCO) Q1 2025 Earnings Call Transcript Bausch + Lomb Corporation (NYSE:BLCO ) Q1 2025 Earnings Conference Call April 30, 2025 8:00 AM ET Company Participants George Gadkowski - Vice President, Investor Relations & Business Insights Brent Saunders - Chairman & Chief Executive Officer Sam Eldessouky - Chief Financial Officer Yehia Hashad - Head, R&D Conference Call Participants Patrick Wood - Morgan Stanley Young Li - Jefferies Joanne Wuensch - Citibank Douglas Miehm - RBC Capital Matt Miksic - Barclays Robbie Marcus - JPMorgan Operator Good morning, and welcome to Bausch + Lomb's First Quarter 2025 Earnings Call. All participants will be in listen-only mode. seekingalpha.com - 2 weeks ago
Bausch + Lomb (BLCO) Reports Q1 Earnings: What Key Metrics Have to Say While the top- and bottom-line numbers for Bausch + Lomb (BLCO) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. zacks.com - 2 weeks ago
Bausch + Lomb (BLCO) Reports Q1 Loss, Misses Revenue Estimates Bausch + Lomb (BLCO) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.03. This compares to earnings of $0.07 per share a year ago. zacks.com - 2 weeks ago
Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market. “We voluntarily recalled these lenses because patient safety dictates every decision. businesswire.com - 3 weeks ago
BLCO or DHR: Which Is the Better Value Stock Right Now? Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better value opportunity right now? zacks.com - 3 weeks ago
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. zacks.com - 3 weeks ago
Bausch + Lomb (BLCO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bausch + Lomb ("Bausch & Lomb" or "the Company") (NYSE:BLCO). Investors who purchased Bausch & Lomb securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/BLCO. accessnewswire.com - 1 month ago
8. Profile Summary

Bausch + Lomb Corporation BLCO

image
COUNTRY CA
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 3.85 B
Dividend Yield 0.00%
Description Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Contact 520 Applewood Crescent, Vaughan, ON, L4K 4B4 https://www.bausch.com
IPO Date May 6, 2022
Employees 13500
Officers Mr. Brenton L. Saunders J.D. Chief Executive Officer & Chairman Mr. A. Robert D. Bailey Executive Vice President & Chief Legal Officer Mr. Frederick J. Munsch Senior Vice President, Controller & Chief Accounting Officer Dr. Manisha A. Narasimhan Ph.D. Chief Corporate Development & Digital Officer Dr. Yehia Hashad M.D., Ph.D. Executive Vice President of Research & Development and Chief Medical officer Mr. Andrew J. Stewart President of Global Pharmaceuticals & International Consumer Mr. T.J. Crawford Chief Communications Officer Mr. Osama A. Eldessouky Executive Vice President & Chief Financial Officer Mr. Alan Waterhouse CPFA, MBA Executive Vice President and Chief Supply Chain & Operations Officer Mr. Jonathon L. Kellerman Chief Compliance Officer